DBV Technologies | DBVT - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amarin USD 645.76M 25.01M 2026-03
BioCryst Pharmaceuticals USD 465.05M 49.11M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
DBV Technologies USD 233.72M 123.22M 2025-12
Esperion Therapeutics USD 462.53M 3.36M 2026-03
Galectin Therapeutics USD 27.65M 1.76M 2024-06
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
Incyte USD 7.34B 381.14M 2026-03
Insmed USD 2.08B 188.7M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
PTC Therapeutics USD 2.87B 29.66M 2026-03
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
United Therapeutics USD 6.71B 1.17B 2026-03